I would like to start a regular segment where I explain the latest findings for therapists!For our momentous first ...

A conductance-based computer model of the Parkinsonian brain circuit shows that deep brain stimulation and rhythmic visual ...

A multimodal imaging and voice-analysis study of early Parkinson's disease reveals that speech impairment arises from dopaminergic loss and striatal connectivity disruption in men but primarily ...

On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...

Researchers developed a probiotic-inspired drug delivery system targeting the gut–brain axis. In Parkinson’s mouse models, it ...

The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...

From Parkinson’s disease to palliative care, music therapy is showing benefits across 10 clinical settings, though the ...

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key ...

Doctors initially told the boy's parents not to worry. But they pressed for years until a rare diagnosis became clear.

Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2Statistically significant improvements in secondary endpoints of ON time without ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease 1 Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated ...

Insulin-like 3 (INSL3) is a peptide hormone important for regulating male reproductive physiology. INSL3 belongs to the insulin/relaxin family of peptide hormones, which are synthesized in cells as ...